Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple MRI spot uterine cancer without a biopsy?

NCT ID NCT07402421

Diagnosis Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether a special type of MRI called diffusion-weighted imaging can accurately tell the difference between benign (non-cancerous) and malignant (cancerous) growths in the lining of the uterus. Researchers will compare the MRI results with the standard method—examining tissue under a microscope after a biopsy. The goal is to see if the MRI can be a reliable, non-invasive alternative for diagnosis. The study plans to enroll 30 women with abnormal uterine bleeding or suspicious findings on ultrasound.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diffusion-weighted magnetic resonance imaging (DWI MRI)
What this could lead to
If successful, DWI MRI could become a reliable non-invasive way to diagnose endometrial lesions, potentially reducing the need for invasive biopsies.
What could go wrong
This is a small, early-stage diagnostic study with only 30 participants. The accuracy may not be high enough to replace biopsy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include female patients presenting with abnormal uterine bleeding or suspected endometrial lesions detected on transvaginal ultrasound. Eligible participants will undergo pelvic MRI including diffusion-weighted imaging, followed by histopathological confirmation through endometrial biopsy or surgical specimens. Patients with prior treatment for the current endometrial pathology (including surgery, hormonal therapy, or radiotherapy), contraindications to MRI (such as cardiac pacemakers or severe claustrophobia), pregnancy, or renal impairment when contrast-enhanced sequences are required will be excluded.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients. * Presenting with abnormal uterine bleeding or suspected endometrial lesions on ultrasound. Exclusion Criteria: * Previous treatment (surgery, hormonal therapy, or radiation) for current endometrial pathology. * Contraindications to MRI (e.g. pacemaker and severe claustrophobia). * Pregnancy or renal impairment if contrast-enhanced sequences are used.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial lesions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sohag University Hospital

    Sohag, Sohag Governorate, Egypt